# Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2012

- Company: [Celldex Therapeutics, Inc.](/companies/cldx.md) (CIK 744218)
- Form: 10-Q
- Filed: 2012-08-09
- Accepted by EDGAR: Aug 9, 2012, 16:01 ET
- Period: 2012-06-30
- Accession: 0001104659-12-056527
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/744218/000110465912056527/a12-13890_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/744218/000110465912056527/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-04-01 to 2012-06-30 | $2.0m | us-gaap:Revenues |
| Revenue | 6 months, 2012-01-01 to 2012-06-30 | $4.4m | us-gaap:Revenues |
| Research and development | 3 months, 2012-04-01 to 2012-06-30 | $11.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2012-01-01 to 2012-06-30 | $21.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2012-04-01 to 2012-06-30 | −$13.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2012-01-01 to 2012-06-30 | −$26.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-04-01 to 2012-06-30 | $411.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2012-01-01 to 2012-06-30 | $844.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2012-04-01 to 2012-06-30 | −$13.8m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months, 2012-01-01 to 2012-06-30 | −$27.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2012-04-01 to 2012-06-30 | −$0.23 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2012-01-01 to 2012-06-30 | −$0.50 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2012-01-01 to 2012-06-30 | −$25.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2012-01-01 to 2012-06-30 | $122.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2012-06-30 | $18.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-06-30 | $80.4m | us-gaap:AssetsCurrent |
| Total assets | at 2012-06-30 | $122.1m | us-gaap:Assets |
| Current liabilities | at 2012-06-30 | $12.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-06-30 | $27.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2012-06-30 | $94.5m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/744218/000110465912056527/a12-13890_110q.htm

Filed Aug 9, 2012.
Source: SEC EDGAR, the filing index for accession 0001104659-12-056527. Last ingested by Listed: Nov 5, 2026, 19:04 ET. No prices; not investment advice.
